Back to Search Start Over

11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis

Authors :
Kay Samuel
Dawn E W Livingstone
Patrick W. F. Hadoke
Jonathan R. Seckl
M. Amine Bouhlel
Zhenguang Zhang
Tak Yung Man
Christopher I. White
Brian R. Walker
Giulia Chinetti-Gbaguidi
Javaid Iqbal
John Savill
Eileen Miller
Ruth Andrew
Katie M. Sullivan
Karen E. Chapman
Tijana Mitić
Bart Staels
Tiina Kipari
Christopher Schrecker
Agnes E. Coutinho
Source :
The FASEB Journal, Kipari, T, Hadoke, P W F, Iqbal, J, Man, T-Y, Miller, E, Coutinho, A E, Zhang, Z, Sullivan, K M, Mitic, T, Livingstone, D E W, Schrecker, C, Samuel, K, White, C I, Bouhlel, M A, Chinetti-Gbaguidi, G, Staels, B, Andrew, R, Walker, B R, Savill, J S, Chapman, K E & Seckl, J R 2013, ' 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis ', The FASEB Journal, vol. 27, no. 4, pp. 1519-1531 . https://doi.org/10.1096/fj.12-219105
Publication Year :
2013
Publisher :
Federation of American Societies for Experimental Biology, 2013.

Abstract

11β-Hydroxysteroid dehydrogenase type-1 (11β-HSD1) converts inert cortisone into active cortisol, amplifying intracellular glucocorticoid action. 11β-HSD1 deficiency improves cardiovascular risk factors in obesity but exacerbates acute inflammation. To determine the effects of 11β-HSD1 deficiency on atherosclerosis and its inflammation, atherosclerosis-prone apolipoprotein E-knockout (ApoE-KO) mice were treated with a selective 11β-HSD1 inhibitor or crossed with 11β-HSD1-KO mice to generate double knockouts (DKOs) and challenged with an atherogenic Western diet. 11β-HSD1 inhibition or deficiency attenuated atherosclerosis (74–76%) without deleterious effects on plaque structure. This occurred without affecting plasma lipids or glucose, suggesting independence from classical metabolic risk factors. KO plaques were not more inflamed and indeed had 36% less T-cell infiltration, associated with 38% reduced circulating monocyte chemoattractant protein-1 (MCP-1) and 36% lower lesional vascular cell adhesion molecule-1 (VCAM-1). Bone marrow (BM) cells are key to the atheroprotection, since transplantation of DKO BM to irradiated ApoE-KO mice reduced atherosclerosis by 51%. 11β-HSD1-null macrophages show 76% enhanced cholesterol ester export. Thus, 11β-HSD1 deficiency reduces atherosclerosis without exaggerated lesional inflammation independent of metabolic risk factors. Selective 11β-HSD1 inhibitors promise novel antiatherosclerosis effects over and above their benefits for metabolic risk factors via effects on BM cells, plausibly macrophages.—Kipari, T., Hadoke, P. W. F., Iqbal, J., Man, T. Y., Miller, E., Coutinho, A. E., Zhang, Z., Sullivan, K. M., Mitic, T., Livingstone, D. E. W., Schrecker, C., Samuel, K., White, C. I., Bouhlel, M. A., Chinetti-Gbaguidi, G., Staels, B., Andrew, R., Walker, B. R., Savill, J. S., Chapman, K. E., Seckl, J. R. 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis.

Details

Language :
English
ISSN :
15306860 and 08926638
Volume :
27
Issue :
4
Database :
OpenAIRE
Journal :
The FASEB Journal
Accession number :
edsair.doi.dedup.....a0c2b651cfa18f0c0da15d344a5c0368